% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Chatterjee:257583,
author = {Chatterjee, Madhurima and Özdemir, Selcuk and Kunadt,
Marcel and Koel-Simmelink, Marleen and Boiten, Walter and
Piepkorn, Lars and Pham, Thang V and Chiasserini, Davide and
Piersma, Sander R and Knol, Jaco C and Möbius, Wiebke and
Mollenhauer, Brit and van der Flier, Wiesje M and Jimenez,
Connie R and Teunissen, Charlotte E and Jahn, Olaf and
Schneider, Anja},
title = {{C}1q is increased in cerebrospinal fluid-derived
extracellular vesicles in {A}lzheimer's disease: {A}
multi-cohort proteomics and immuno-assay validation study.},
journal = {Alzheimer's and dementia},
volume = {19},
number = {11},
issn = {1552-5260},
address = {Hoboken, NJ},
publisher = {Wiley},
reportid = {DZNE-2023-00459},
pages = {4828 - 4840},
year = {2023},
abstract = {Extracellular vesicles (EVs) may propagate and modulate
Alzheimer's disease (AD) pathology. We aimed to
comprehensively characterize the proteome of cerebrospinal
fluid (CSF) EVs to identify proteins and pathways altered in
AD.CSF EVs were isolated by ultracentrifugation (Cohort 1)
or Vn96 peptide (Cohort 2) from non-neurodegenerative
controls (n = 15, 16) and AD patients (n = 22, 20,
respectively). EVs were subjected to untargeted quantitative
mass spectrometry-based proteomics. Results were validated
by enzyme-linked immunosorbent assay (ELISA) in Cohorts 3
and 4, consisting of controls (n = 16, n = 43, (Cohort3,
Cohort4)), and patients with AD (n = 24, n = 100).We found >
30 differentially expressed proteins in AD CSF EVs involved
in immune-regulation. Increase of C1q levels in AD compared
to non-demented controls was validated by ELISA (∼ 1.5
fold, p (Cohort 3) = 0.03, p (Cohort 4) = 0.005).EVs may be
utilized as a potential biomarker and may play a so far
unprecedented role in immune-regulation in AD.},
keywords = {Humans / Alzheimer Disease: pathology / Complement C1q /
Proteomics / Amyloid beta-Peptides: metabolism / Peptide
Fragments: cerebrospinal fluid / Biomarkers: cerebrospinal
fluid / Extracellular Vesicles: metabolism / tau Proteins:
cerebrospinal fluid / Cognitive Dysfunction: cerebrospinal
fluid / Complement C1q (NLM Chemicals) / Alzheimer's disease
(AD) (Other) / biomarker (Other) / cerebrospinal fluid (CSF)
(Other) / complement (Other) / extracellular vesicles
(Other) / immune system (Other) / mild cognitive impairment
(MCI) (Other) / proteomics (Other) / Amyloid beta-Peptides
(NLM Chemicals) / Peptide Fragments (NLM Chemicals) /
Biomarkers (NLM Chemicals) / tau Proteins (NLM Chemicals)},
cin = {AG Schneider},
ddc = {610},
cid = {I:(DE-2719)1011305},
pnm = {353 - Clinical and Health Care Research (POF4-353)},
pid = {G:(DE-HGF)POF4-353},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:37023079},
doi = {10.1002/alz.13066},
url = {https://pub.dzne.de/record/257583},
}